Effect of the TNFα-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome

Annals of Nutrition and Metabolism

Volumn 53, Issue 2, 2008, Pages 117-121

  Pérez Castrillón, José Luis ^a,b   Vega, Gemma ^a   Abad, Laura ^a   Sanz Cantalapiedra, Alberto ^a   Gonzalez Sagredo, Manuel ^a,b   De Luis, Daniel ^a,b   Duenas Laita, Antonio ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b RD 056/0013 RETICEF   (Spain)

Author keywords

308 G A polymorphism; Atorvastatin; Bone mineral density; TNF

Indexed keywords

ALKALINE PHOSPHATASE; ATORVASTATIN; CALCIUM; DEOXYPYRIDINOLINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MAGNESIUM; OSTEOCALCIN; PHOSPHORUS; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; AMINO ACID; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE REMODELING; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LUMBAR SPINE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PHARMACOGENOMICS; PHOSPHATE BLOOD LEVEL; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RADIODENSITOMETRY; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DOSE RESPONSE; FEMUR NECK; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; PHOTON ABSORPTIOMETRY; RISK FACTOR; URINE;

ABSORPTIOMETRY, PHOTON; ACUTE CORONARY SYNDROME; AMINO ACIDS; ANTICHOLESTEREMIC AGENTS; BONE DENSITY; CALCIUM; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; GENOTYPE; HEPTANOIC ACIDS; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; PHOSPHORUS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PYRROLES; RISK FACTORS; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55449107464     PISSN: 02506807     EISSN: None     Source Type: Journal    
DOI: 10.1159/000170886     Document Type: Article

References (25)

1. Kado DM, Browner WS, Blackwell T, Gore R, Cummings SR: Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res 2000;15:1974-1980.
2. Bauer DC, Palermo L, Black D, Cauley JA: Quantitative ultrasound and mortality: a prospective study. Osteoporos Int 2002;13:606-612.
3. Marcovitz PA, Tran HH, Franklin BA, O'Neill WW, Yerkey M, Boura J, Kleerekoper M, Dickinson CZ: Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol 2005;96:1059-1063.
4. Vogt MT, Cauley JA, Kuller LH, Nevitt MC: Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res 1997;12:283-289.
5. Tanko LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR: Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005;20:1912-1920.
6. Barengolts EI, Berman M, Kukreja SC, Kouznetsova T, Lin C, Chomka EV: Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 1998;62:209-213.
7. Sinnott B, Syed I, Sevrukov A, Barengolts E: Coronary calcification and osteoporosis in men and postmenopausal women are independent processes associated with aging. Calcif Tissue Int 2006;78:195-202.
8. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
9. Pacifici R: Estrogen, cytokines and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996;11:1043-1051.
10. Pérez Castrillón JL, Abad L, Vega G, Sanz-Cantalapiedra A, Sanchez S, Hernandez G, Dueñas Laita A: Effects of statins on bone markers, bone mineral density and fractures. Possible role in osteoporosis treatment. Curr Pharm Anal 2006;2:161-168.
11. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS: Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990;65:297-302.
12. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa S, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio T, Martin TJ, Suda T: Tumor necrosis factor stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-278.
13. Romas E, Martin TJ: Cytokines in the pathogenesis of osteoporosis. Osteoporos Int 1997;7:S47-S53.
14. Goldring SR, Goldring MB: Eating bone or adding it: the Wnt pathway decides. Nat Med 2007;13:133-134.
15. Gander ML, Fischer JE, Maly FE, Von Känel R: Effect of the G-308A polymorphism of the tumor necrosis factor (TNF)-α gene promoter site on plasma levels of TNF-α and C-reactive protein in smokers: a cross-sectional study. BMC Cardiovasc Disord 2004;4:17-23.
16. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mathieu P, Malaise M, De Groote D, Louis R, Belaiche J: Tumor necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS) stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-406.
17. Bouma G, Crusius JB, Oudkerk Pool M, Kolkman JJ, Von Blomberg BM, Kostense PJ, Giphart MJ, Schreuder GM, Meuwissen SG, Pena AS: Secretion of tumor necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456-463.
18. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
19. Wennberg P, Nordström P, Lorentzon R, Lerner UH, Lorentzon M: TNF-α gene polymorphism and plasma TNF-α levels are related to lumbar spine bone area in healthy female caucasian adolescents. Eur J Endocrinol 2002;146:629-634.
20. Chen HY, Chen WC, Hsu CM, Tsai FJ, Tsai CH: Tumor necrosis factor α, CYP 17, urokinase and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis. Eur J Obstet Gynecol Reprod Biol 2005;122:73-78.
21. Haenni A, Öhrvall M, Lithell H: Serum magnesium status during lipid-lowering drug treatment in non-insulin dependent diabetic patients. Metabolism 2001;50:1147-1151.
22. Westerberg M, Bengtsson A, Ricksten A, Jeppsson A: Tumor necrosis factor gene polymorphisms and inflammatory response in artery coronary bypass grafting patients. Scand Cardiovasc J 2004;38:312-317.
23. Fontova R, Gutierrez C, Vendrell J, Broch M, Vendrell I, Simon I, Fernandez-Real JM, Richart C: Bone mineral mass is associated with interleukin 1 receptor autoantigen and TNF-alpha gene polymorphism in postmenopausal Mediterranean women. J Endocrinol Invest 2002;25:684-690.
24. Elghannam H, Tavackoli S, Ferlic L, Gotto AM, Ballantyne CM, Marian AJ: A prospective study of genetic markers of susceptibility to infection and inflammation and the severity, progression and regression of coronary atherosclerosis and its response to therapy. J Mol Med 2000;78:562-568.
25. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG: Association of TNF-alpha-308G/A polymorphism with responsiveness to TNF-α-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006;27:157-161.